In addition, antiangiogenic medications, such as tyrosine kinase inhibitors5 or monoclonal antibodies targeting vascular endothelial growth factor (VEGF), have been used as adjuvant therapies for the management of solid tumors and cancer-related conditions such as bone metastases (See Table 1). Here, VEGFA is linked to cancer.